TONGHUA GOLDEN-HORSE(000766)2023-05-23 07:14Group 1: Company Overview and Activities - The company is Tonghua Jinma Pharmaceutical Group Co., Ltd., with stock code 000766 [1] - The investor relations activity was held on May 22, 2023, via an online platform [1] - Participants included the company's board members and investors [1] Group 2: New Drug Development - The new drug, Amber Hydrogen Amino Acids Tablets, is in Phase III clinical trials, currently undergoing inspection and correction [1][2][3] - The company is closely monitoring the drug's development and will disclose information as required by regulations [1][2][3] - Reports suggest that 13 products, including the new drug, are expected to be launched before 2024 [1] Group 3: Financial and Operational Concerns - The company is addressing short-term and long-term debt management to reduce annual interest expenses [2] - Marketing expenses are currently aligned with sales scale, but the company plans to enhance management to control these costs [2] - The liquidity issues in the secondary market are acknowledged, and the company aims to maintain steady operational performance [2] Group 4: Regulatory and Disclosure Practices - The company emphasizes compliance with information disclosure obligations regarding new drug approvals and developments [1][2][3] - There is a focus on maintaining confidentiality around new drug progress, leading to standardized responses to inquiries [3]